Listar Artículos, capítulos, libros...UCO por autor "cbc9005e-eea1-4091-8e59-68e730f446b1"

Mostrando ítems 1-15 de 15

    • A Multiplex Test Assessing MiR663ame and VIMme in Urine Accurately Discriminates Bladder Cancer from Inflammatory Conditions 

      Monteiro-Reis, Sara; Blanca, Ana; Tedim-Moreira, Joana; Carneiro, Isa; Montezuma, Diana; Monteiro, Paula; Oliveira, Jorge; Antunes, Luís; Henrique, Rui; López-Beltrán, Antonio; Jerónimo, Carmen (MDPI, 2020)
      Bladder cancer (BlCa) is a common malignancy with significant morbidity and mortality. Current diagnostic methods are invasive and costly, showing the need for newer biomarkers. Although several epigenetic-based biomarkers ...

    • Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 

      Aurilio, Gaetano; Cimadamore, Alessia; Mazzucchelli, Roberta; López-Beltrán, Antonio; Verri, Elena; Scarpelli, Marina; Massari, Francesco; Cheng, Liang; Santoni, Matteo; Montironi, Rodolfo (MDPI, 2020)
      Around 80–90% of prostate cancer (PCa) cases are dependent on androgens at initial diagnosis; hence, androgen ablation therapy directed toward a reduction in serum androgens and the inhibition of androgen receptor (AR) is ...

    • Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic 

      Cimadamore, Alessia; Cheng, Liang; Massari, Francesco; Santoni, Matteo; Pepi, Laura; Franzese, Carmine; Scarpelli, Marina; López-Beltrán, Antonio; Galosi, Andrea B.; Montironi, Rodolfo (MDPI, 2021)

    • Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma 

      Mollica, Veronica; Rizzo, Alessandro; Montironi, Rodolfo; Cheng, Liang; Giunchi, Francesca; Schiavina, Riccardo; Santoni, Matteo; Fiorentino, Michelangelo; López-Beltrán, Antonio; Brunocilla, Eugenio; Brandi, Giovanni; Massari, Francesco (MDPI, 2020)
      Urothelial carcinoma (UC) is a frequent cause of cancer-related deaths worldwide. Metastatic UC has been historically associated with poor prognosis, with a median overall survival of approximately 15 months and a 5-year ...

    • Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy 

      Cimadamore, Alessia; Gasparrini, Silvia; Massari, Francesco; Santoni, Matteo; Cheng, Liang; López-Beltrán, Antonio; Scarpelli, Marina; Montironi, Rodolfo (MDPI, 2019)
      Liquid biopsy, based on the circulating tumor cells (CTCs) and cell-free nucleic acids has potential applications at multiple points throughout the natural course of cancer, from diagnosis to follow-up. The advantages of ...

    • Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer 

      López-Beltrán, Antonio; Cimadamore, Alessia; Blanca, Ana; Massari, Francesco; Vau, Nuno; Scarpelli, Marina; Cheng, Liang; Montironi, Rodolfo (MDPI, 2021)
      A number of immune checkpoint inhibitors (ICIs) have been approved as first-line therapy in case of cisplatin-ineligible patients or as second-line therapy for patients with metastatic urothelial carcinoma (mUC) of the ...

    • Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing 

      López-Beltrán, Antonio; López-Ríos, Fernando; Montironi, Rodolfo; Wildsmith, Sophie; Eckstein, Markus (MDPI, 2021)
      Immuno-oncology (IO) agents (anti–programmed cell death 1 (PD-1) and anti–programmed cell death-ligand 1 (PD-L1)) are approved as first- and second-line treatments for metastatic UC. PD-L1 expression levels in UC tumors ...

    • Molecular Classification of Bladder Urothelial Carcinoma Using NanoString-Based Gene Expression Analysis 

      López-Beltrán, Antonio; Blanca, Ana; Cimadamore, Alessia; Gogna, Rajan; Montironi, Rodolfo; Cheng, Liang (MDPI, 2021)
      Molecular classification of bladder carcinoma is a relevant topic in modern bladder cancer oncology due to its potential to improve oncological outcomes. The available molecular classifications are generally based on ...

    • New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents? 

      Aurilio, Gaetano; Cimadamore, Alessia; Santoni, Matteo; Nolé, Franco; Scarpelli, Marina; Massari, Francesco; López-Beltrán, Antonio; Cheng, Liang; Montironi, Rodolfo (MDPI, 2020)
      Medical treatment for metastatic castration-resistant prostate cancer (mCRPC) patients has progressively been evolving from a nonspecific clinical approach to genomics-oriented therapies. The scientific community is in ...

    • Prostate Cancer in 2021: Novelties in Prognostic and Therapeutic Biomarker Evaluation 

      Cimadamore, Alessia; Mazzucchelli, Roberta; López-Beltrán, Antonio; Massari, Francesco; Santoni, Matteo; Scarpelli, Marina; Cheng, Liang; Montironi, Rodolfo (MDPI, 2021)
      The 2021 novelties in prognostic and therapeutic tissue markers in patients with prostate cancer (PCa) can be subdivided into two major groups. The first group is related to prognostic markers based on morphological and ...

    • Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer 

      Di Nunno, Vincenzo; Gatto, Lidia; Santoni, Matteo; Cimadamore, Alessia; López-Beltrán, Antonio; Cheng, Liang; Scarpelli, Marina; Montironi, Rodolfo; Massari, Francesco (Frontiers, 2018)
      Management of localized and advanced prostate cancer benefits from several therapeutic options with a surprising improvement in terms of clinical outcome. The selection of patients more likely to benefit from a specific ...

    • Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor 

      Mollica, Veronica; Di Nunno, Vincenzo; Gatto, Lidia; Santoni, Matteo; Scarpelli, Marina; Cimadamore, Alessia; López-Beltrán, Antonio; Cheng, Liang; Battelli, Nicola; Montironi, Rodolfo; Massari, Francesco (MDPI, 2019)
      The development of new systemic agents has led us into a “golden era” of management of metastatic renal cell carcinoma (RCC). Certainly, the approval of immune-checkpoint inhibitors and the combination of these with ...

    • T1 bladder carcinoma with variant histology: pathological features and clinical significance 

      López-Beltrán, Antonio; Blanca, Ana; Cimadamore, Alessia; Montironi, Rodolfo; Luque, Rafael J.; Volavšek, Metka; Chen, Liang (Springer, 2022)
      The aim of the study was to stratify high-grade T1 (HGT1) bladder urothelial carcinoma into risk categories based on the presence of variant histology when compared to conventional urothelial carcinoma. The clinicopathological ...

    • The Human Microbiota and Prostate Cancer: Friend or Foe? 

      Massari, Francesco; Mollica, Veronica; Di Nunno, Vincenzo; Gatto, Lidia; Santoni, Matteo; Scarpelli, Marina; Cimadamore, Alessia; López-Beltrán, Antonio; Cheng, Liang; Battelli, Nicola; Montinori, Rodolfo; Brandi, Giovanni (MDPI, 2019)
      The human microbiome is gaining increasing attention in the medical community, as knowledge on its role not only in health but also in disease development and response to therapies is expanding. Furthermore, the connection ...

    • Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer 

      Cimadamore, Alessia; Aurilio, Gaetano; Nolé, Franco; Massari, Francesco; Scarpelli, Marina; Santoni, Matteo; López-Beltrán, Antonio; Cheng, Liang; Montironi, Rodolfo (MDPI, 2020)
      Current developments in the treatment of genitourinary tumors underline the unmet clinical need for biomarkers to improve decision-making in a challenging clinical setting. The detection of circulating tumor cells (CTCs) ...